Results 181 to 190 of about 22,035 (254)

Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways. [PDF]

J Clin Pharmacol
Arora P, Liu H, Ling J, Hindman JT, Marathe DD.   +4 more
europepmc   +1 more source

A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs. [PDF]

Clin Pharmacokinet
Coumau C, Csajka C.
europepmc   +1 more source

Mapping the Gut Microbiota Composition in the Context of Raltegravir, Dolutegravir, and Bictegravir-A Scoping Review. [PDF]

Int J Mol Sci
Gáspár Z, Lakatos B.
europepmc   +1 more source

DEFINE: A Prospective, Randomized, Phase 4 Trial to Assess a Protease Inhibitor-Based Regimen Switch Strategy to Manage Integrase Inhibitor-Related Weight Gain. [PDF]

Clin Infect Dis
Anderson D, Ramgopal M, Hagins DP, Lee J, Simonson RB, Hsu TH, Xu P, Ahmad N, Short WR.   +8 more
europepmc   +1 more source

A novel measure of antiretroviral activity in CSF and association with HIV persistence and cognitive function. [PDF]

AIDS
Avedissian SN, McCarthy C, Bosch RJ, Spudich S, Gandhi RT, McMahon DK, Eron JJ, Fletcher CV.   +7 more
europepmc   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

New England Journal of Medicine, 2021
BACKGROUND The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this
Stephen Ian Walimbwa, Barbara Castelnuovo, Agnes N Kiragga   +2 more
exaly   +2 more sources

Lack of antiviral activity of darunavir against SARS-CoV-2

International Journal of Infectious Diseases, 2020
Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being ...
Denisa Bojkova, Jindrich Cinatl, Ellen Van Damme   +2 more
exaly   +2 more sources

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat

Biomedicines, 2021
A major challenge in the management of antiretroviral therapy (ART) is to improve the patient’s adherence, reducing the burden caused by the high number of drugs that compose the treatment regimens for human immunodeficiency virus positive (HIV ...
Nicoleta Negrut, Simona Bungau
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Quality by design tool-evaluated stability-indicating ultra-performance liquid chromatography method for the determination of drugs (ritonavir and darunavir) used to treat the human immunodeficiency virus/acquired immunodeficiency syndrome.

Biomedical chromotography, 2023
Ritonavir and darunavir were examined using a ultra-performance liquid chromatography (UPLC) approach in pharmaceutical dosage forms. The small number of analytical studies that are currently available do not demonstrate the method's stability or nature.
Jyothsna Menda, Phani Raja Kanuparthy, N. K. Katari, Leela Prasad Kowtharapu, Santhosh Kumar Ettaboina, Surya Prakash Rao Pydimarry   +5 more
semanticscholar   +1 more source